EHA 2024 Insights: Zanubrutinib vs. Acalabrutinib in B-cell Malignancies - An AE-Based Economic Analysis | VuMedi

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Zanubrutinib vs. Acalabrutinib in B-cell Malignancies - An AE-Based Economic Analysis

By Insights from 2024 EHA Annual Meeting FEATURING Talha Munir

By Insights from 2024 EHA Annual Meeting FEATURING Talha Munir

73 views

July 8, 2024

AE-Based Comparison: Zanubrutinib & Acalabrutinib Economic Analysis

00:00

Cost Saving and QALY Gains with Zanubrutinib for B-cell Malignancies

03:06

1 Comment

Login to view comments. Click here to Login